Siemens Healthineers vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Siemens Healthineers AG (SHL.XETRA)

Q3 202628 Jul – 23 Sep 2026

▲3

Siemens Healthineers: profit outlook raised, revenue trimmed, new deals build demand

Profit guidance raised, revenue growth cut Siemens Healthineers raised its fiscal 2026 earnings per share forecast to €2.35–2.45 but lowered comparable revenue growth to 3.5–4.0%. Profit is improving, but slower sales growth and tariff/pricing pressures keep a lid on the stock.
This is the single biggest company-specific event of the period and directly explains the mixed share price reaction.
New partnerships expand cancer and liver diagnostics Siemens Healthineers teamed up with Novo on non-invasive liver diagnostics and with Thailand's PRINC on advanced cancer care, including radiotherapy equipment. These deals open recurring revenue streams and embed its tools in more hospitals.
Fresh commercial wins show real demand for its products and support future revenue growth.
Surveys and reports point to strong lab and imaging demand A Siemens Healthineers survey found 54% of U.S. healthcare executives prioritize lab equipment upgrades, and a company report highlighted stroke care gaps in Southeast Asia. Both signal growing demand for its diagnostic and imaging solutions.
These demand indicators support the bull case for Siemens Healthineers' core segments.
AI imaging and MRI markets forecast to grow strongly Industry reports project the AI medical imaging market will reach $19.4 billion by 2035 and the MRI systems market $9.68 billion by 2031, with Siemens Healthineers named a key player. This supports long-term demand for its imaging and AI products.
Market growth forecasts reinforce the structural growth story behind the stock.

August 202628 Jul – 23 Sep 2026

▲3

Siemens Healthineers: profit outlook raised, revenue trimmed, new deals build demand

Profit guidance raised, revenue growth cut Siemens Healthineers raised its fiscal 2026 earnings per share forecast to €2.35–2.45 but lowered comparable revenue growth to 3.5–4.0%. Profit is improving, but slower sales growth and tariff/pricing pressures keep a lid on the stock.
This is the single biggest company-specific event of the period and directly explains the mixed share price reaction.
New partnerships expand cancer and liver diagnostics Siemens Healthineers teamed up with Novo on non-invasive liver diagnostics and with Thailand's PRINC on advanced cancer care, including radiotherapy equipment. These deals open recurring revenue streams and embed its tools in more hospitals.
Fresh commercial wins show real demand for its products and support future revenue growth.
Surveys and reports point to strong lab and imaging demand A Siemens Healthineers survey found 54% of U.S. healthcare executives prioritize lab equipment upgrades, and a company report highlighted stroke care gaps in Southeast Asia. Both signal growing demand for its diagnostic and imaging solutions.
These demand indicators support the bull case for Siemens Healthineers' core segments.
AI imaging and MRI markets forecast to grow strongly Industry reports project the AI medical imaging market will reach $19.4 billion by 2035 and the MRI systems market $9.68 billion by 2031, with Siemens Healthineers named a key player. This supports long-term demand for its imaging and AI products.
Market growth forecasts reinforce the structural growth story behind the stock.

Latest28 Jul – 23 Sep 2026

▲3

Siemens Healthineers: profit outlook raised, revenue trimmed, new deals build demand

Profit guidance raised, revenue growth cut Siemens Healthineers raised its fiscal 2026 earnings per share forecast to €2.35–2.45 but lowered comparable revenue growth to 3.5–4.0%. Profit is improving, but slower sales growth and tariff/pricing pressures keep a lid on the stock.
This is the single biggest company-specific event of the period and directly explains the mixed share price reaction.
New partnerships expand cancer and liver diagnostics Siemens Healthineers teamed up with Novo on non-invasive liver diagnostics and with Thailand's PRINC on advanced cancer care, including radiotherapy equipment. These deals open recurring revenue streams and embed its tools in more hospitals.
Fresh commercial wins show real demand for its products and support future revenue growth.
Surveys and reports point to strong lab and imaging demand A Siemens Healthineers survey found 54% of U.S. healthcare executives prioritize lab equipment upgrades, and a company report highlighted stroke care gaps in Southeast Asia. Both signal growing demand for its diagnostic and imaging solutions.
These demand indicators support the bull case for Siemens Healthineers' core segments.
AI imaging and MRI markets forecast to grow strongly Industry reports project the AI medical imaging market will reach $19.4 billion by 2035 and the MRI systems market $9.68 billion by 2031, with Siemens Healthineers named a key player. This supports long-term demand for its imaging and AI products.
Market growth forecasts reinforce the structural growth story behind the stock.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.